CD19 and Miyoshi myopathy: Based on the data obtained for 101 consecutive MM patients, the increased total PB counts of CD19+ B cells at pre-AHSCT is significantly associated with improved 2-year PFS (83% vs. 53%) and OS (93% vs. 63%).